|
NESP-55 |
Secretogranin II |
|||
Pulmonary typical carcinoids |
1/151 |
14/151 |
14/141 |
||
Ileal typical carcinoid |
0/111 |
11/111 |
10/101 |
9/101 |
|
Gastric typical carcinoid |
0/41 |
4/41 |
3/31 |
2/31 |
|
Rectal typical carcinoid |
1/41 |
1/41 |
4/41 |
4/41 |
|
Pancreatic endocrine tumour |
14/191 |
19/191 |
18/181 |
18/181 |
|
Adrenal phaeochromocytoma |
10/101 |
10/101 |
6/61 |
6/61 |
|
NESP-55 may stain benign pancreatic endocrine tumours more strongly than malignant tumours:
Diffuse |
Focal |
|||
Functional |
Insulinoma |
5/6 |
1/6 |
|
Gastrinoma |
0/2 |
2/2 |
||
VIPoma |
0/1 |
1/1 |
||
Glucagonoma |
0/1 |
0/1 |
||
Acromegaly |
0/1 |
0/1 |
||
Non-functional |
1/7 |
4/7 |
||
No metastases |
6/12 |
5/12 |
||
With metastases |
0/7 |
3/7 |
||
Differentiation of pheochromocytomas and pancreatic endocrine tumours (positive for NESP-55) from pulmonary, gastric, ileal and rectal carcinoids (negative for NESP-55).
Possibly in the differentiation of benign (positive) from malignant (negative) pancreatic endocrine tumours: this contradicts the proposed use to identify the site of origin of a metastatic neuroendocrine tumour.
References
This page last revised 18.11.2004.
©SMUHT/PW Bishop